Last reviewed · How we verify
Eliquis — mechanism of action
Apixaban selectively inhibits Factor Xa, decreasing thrombin generation and thrombus development.
How Eliquis works
Apixaban selectively inhibits Factor Xa, decreasing thrombin generation and thrombus development.
Detailed mechanism
Apixaban is a selective inhibitor of FXa that does not require antithrombin III for antithrombotic activity. It inhibits both free and clot-bound FXa, as well as prothrombinase activity. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development. Apixaban has no direct effect on platelet aggregation but indirectly inhibits platelet aggregation induced by thrombin.
| Molecular target | Factor Xa (FXa) |
|---|---|
| Drug class | Factor Xa inhibitor |
See also
- Full profile: Eliquis
- Side effects: /side-effects
- Dosage & administration: /dosage
- Cost & pricing: /cost
- Drug interactions: /interactions
- Clinical trials: /clinical-trials
- Patents & exclusivity: /patents
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing